• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

克服-TKD突变型混合表型急性白血病患者移植后移植物失败和腺病毒感染:一例报告

Overcoming post-transplant graft failure and adenovirus infection in a patient with -TKD-mutated mixed-phenotype acute leukemia: A case report.

作者信息

Takada Yusuke, Kurosawa Shuhei, Ueki Toshimitsu, Najima Yuho, Wakita Satoshi, Yamaguchi Hiroki, Yokota Takako, Hibi Masaki, Hirahara Ayumi, Yoshida Tsutomu, Okubo So, Masuda Moe, Nakayama Hitomi, Sakurai Aki, Ito Chisako, Aisa Yoshinobu, Nakazato Tomonori

机构信息

Department of Hematology Yokohama Municipal Citizen's Hospital Yokohama Japan.

Department of Hematology Nagano Red Cross Hospital Nagano Japan.

出版信息

EJHaem. 2024 Jun 17;5(4):802-809. doi: 10.1002/jha2.956. eCollection 2024 Aug.

DOI:10.1002/jha2.956
PMID:39157616
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11327757/
Abstract

Mixed-phenotype acute leukemia (MPAL) with -TKD mutations is a rare and challenging subtype of leukemia. Effective management strategies are crucial for improving patient outcomes. A 31-year-old man with -TKD-mutated MPAL achieved hematological remission through the JALSG ALL202-O protocol and gilteritinib, followed by cord blood transplantation (CBT). Post-transplant complications included adenovirus-induced hemorrhagic cystitis, managed with bladder irrigation and ribavirin, and engraftment failure, necessitating a second CBT on Day 35. Subsequent adenoviral conjunctivitis resolved with vidarabine. The patient achieved neutrophil engraftment by Day 76 and was discharged on Day 173 without relapse. This case highlights the importance of vigilant supportive care and tailored therapy in managing MPAL with mutations, especially in the context of post-transplant complications.

摘要

伴有-TKD突变的混合表型急性白血病(MPAL)是一种罕见且具有挑战性的白血病亚型。有效的管理策略对于改善患者预后至关重要。一名患有-TKD突变型MPAL的31岁男性通过JALSG ALL202-O方案和吉列替尼实现了血液学缓解,随后进行了脐血移植(CBT)。移植后并发症包括腺病毒诱导的出血性膀胱炎,通过膀胱冲洗和利巴韦林进行治疗,以及植入失败,需要在第35天进行第二次CBT。随后的腺病毒性结膜炎通过阿糖腺苷得以缓解。患者在第76天实现了中性粒细胞植入,并于第173天出院,无复发。该病例强调了在管理伴有突变的MPAL时,尤其是在移植后并发症的情况下,警惕性支持治疗和个体化治疗的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2292/11327757/a2730bc8df59/JHA2-5-802-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2292/11327757/f919374b2263/JHA2-5-802-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2292/11327757/a2730bc8df59/JHA2-5-802-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2292/11327757/f919374b2263/JHA2-5-802-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2292/11327757/a2730bc8df59/JHA2-5-802-g002.jpg

相似文献

1
Overcoming post-transplant graft failure and adenovirus infection in a patient with -TKD-mutated mixed-phenotype acute leukemia: A case report.克服-TKD突变型混合表型急性白血病患者移植后移植物失败和腺病毒感染:一例报告
EJHaem. 2024 Jun 17;5(4):802-809. doi: 10.1002/jha2.956. eCollection 2024 Aug.
2
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.在 3 期 ADMIRAL 试验中,比较 gilteritinib 与挽救化疗用于 FLT3 突变的复发/难治性急性髓系白血病患者移植后的结局。
Transplant Cell Ther. 2023 Apr;29(4):265.e1-265.e10. doi: 10.1016/j.jtct.2022.12.006. Epub 2022 Dec 13.
3
Successful bridge therapy of gilteritinib to cord blood transplantation in relapsed acute myeloid leukemia after bone marrow transplantation.吉特替尼桥接治疗异基因造血干细胞移植后复发的急性髓系白血病。
J Infect Chemother. 2021 Apr;27(4):639-641. doi: 10.1016/j.jiac.2020.11.003. Epub 2020 Nov 17.
4
Gilteritinib Combined with Azacitidine as Salvage Therapy for B/Myeloid Mixed Phenotype Acute Leukemia.吉瑞替尼联合阿扎胞苷作为B/髓系混合表型急性白血病的挽救治疗
Cureus. 2022 Mar 29;14(3):e23618. doi: 10.7759/cureus.23618. eCollection 2022 Mar.
5
Genomic Landscape of Mixed-Phenotype Acute Leukemia.混合表型急性白血病的基因组景观。
Int J Mol Sci. 2022 Sep 24;23(19):11259. doi: 10.3390/ijms231911259.
6
Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia.急性早幼粒细胞白血病脑膜复发时FLT3-TKD突变亚克隆的演变
Cold Spring Harb Mol Case Stud. 2016 Sep;2(5):a001123. doi: 10.1101/mcs.a001123.
7
Co-occurrence of -TKD and mutations defines a highly favorable prognostic AML group.-TKD与突变同时出现定义了一个预后高度良好的急性髓系白血病组。
Blood Adv. 2017 Aug 17;1(19):1546-1550. doi: 10.1182/bloodadvances.2017009019. eCollection 2017 Aug 22.
8
Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy.FLT3+急性髓系白血病患者的治疗管理:病例报告及对吉列替尼单药治疗的关注
Pharmgenomics Pers Med. 2022 Apr 22;15:393-407. doi: 10.2147/PGPM.S346688. eCollection 2022.
9
[Detection of point mutation at second tyrosine kinase domain of FLT3 gene in acute myeloid leukemia].[急性髓系白血病中FLT3基因第二个酪氨酸激酶结构域点突变的检测]
Zhonghua Xue Ye Xue Za Zhi. 2005 Jun;26(6):335-8.
10
Outcome of Relapsed or Refractory -Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse-Bordeaux DATAML Registry Study.第二代FLT3酪氨酸激酶抑制剂问世之前复发或难治性突变型急性髓系白血病的结局:图卢兹-波尔多DATAML注册研究
Cancers (Basel). 2020 Mar 25;12(4):773. doi: 10.3390/cancers12040773.

引用本文的文献

1
Treating Adenovirus Infection in Transplant Populations: Therapeutic Options Beyond Cidofovir?治疗移植人群中的腺病毒感染:除西多福韦之外的治疗选择?
Viruses. 2025 Apr 23;17(5):599. doi: 10.3390/v17050599.

本文引用的文献

1
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of .吉特替尼作为伴有. 内部串联重复突变的 AML 移植后维持治疗。
J Clin Oncol. 2024 May 20;42(15):1766-1775. doi: 10.1200/JCO.23.02474. Epub 2024 Mar 12.
2
Acute leukemia of ambiguous lineage, not otherwise specified with FLT3-ITD mutation and a possible origin in the common lymphoid progenitor.谱系不明确的急性白血病,未另行指定,伴有FLT3-ITD突变,可能起源于常见淋巴样祖细胞。
Cytometry B Clin Cytom. 2023 Sep;104(5):400-403. doi: 10.1002/cyto.b.22134. Epub 2023 May 31.
3
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.
世界卫生组织血液淋巴肿瘤分类第五版:髓系和组织细胞/树突状肿瘤。
Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22.
4
Improved trends in survival and engraftment after single cord blood transplantation for adult acute myeloid leukemia.成人急性髓系白血病患者行单份脐带血移植后生存和植入情况的改善趋势。
Blood Cancer J. 2022 May 25;12(5):81. doi: 10.1038/s41408-022-00678-6.
5
Gilteritinib Combined with Azacitidine as Salvage Therapy for B/Myeloid Mixed Phenotype Acute Leukemia.吉瑞替尼联合阿扎胞苷作为B/髓系混合表型急性白血病的挽救治疗
Cureus. 2022 Mar 29;14(3):e23618. doi: 10.7759/cureus.23618. eCollection 2022 Mar.
6
Adenoviral Infections in Bone Marrow Transplanted Adult Patients: A Review of the 44 Cases Reported in the Last 25 Years.骨髓移植成年患者中的腺病毒感染:过去25年报告的44例病例综述
Cureus. 2021 Nov 24;13(11):e19865. doi: 10.7759/cureus.19865. eCollection 2021 Nov.
7
Use of midostaurin in mixed phenotype acute leukemia with FLT3 mutation: A case series.米哚妥林治疗伴有 FLT3 突变的混合表型急性白血病:病例系列研究。
Eur J Haematol. 2022 Feb;108(2):163-165. doi: 10.1111/ejh.13717. Epub 2021 Oct 26.
8
The successful use of inhibitors in -positive mixed phenotype acute leukemia.抑制剂在阳性混合表型急性白血病中的成功应用。
Leuk Lymphoma. 2020 Dec;61(13):3275-3277. doi: 10.1080/10428194.2020.1802451. Epub 2020 Aug 6.
9
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.FLT3 抑制剂在急性髓系白血病中的应用:十个常见问题。
Leukemia. 2020 Mar;34(3):682-696. doi: 10.1038/s41375-019-0694-3. Epub 2020 Jan 9.
10
Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia.FLT3 酪氨酸激酶结构域突变作为急性髓系白血病预后因素的意义。
Int J Hematol. 2019 Nov;110(5):566-574. doi: 10.1007/s12185-019-02720-z. Epub 2019 Aug 20.